The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.
Clinical trial NCT05333588 · UNKNOWN
Trial details
- NCT number
- NCT05333588
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-02-15
- Primary completion
- 2024-02-15
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.